KR101923103B1 - 릴피비린 hcl 및 테노포비어 디소프록실 푸마레이트를 포함하는 치료 조성물 - Google Patents

릴피비린 hcl 및 테노포비어 디소프록실 푸마레이트를 포함하는 치료 조성물 Download PDF

Info

Publication number
KR101923103B1
KR101923103B1 KR1020137015719A KR20137015719A KR101923103B1 KR 101923103 B1 KR101923103 B1 KR 101923103B1 KR 1020137015719 A KR1020137015719 A KR 1020137015719A KR 20137015719 A KR20137015719 A KR 20137015719A KR 101923103 B1 KR101923103 B1 KR 101923103B1
Authority
KR
South Korea
Prior art keywords
layer
delete delete
tenofovir
tablets
emtricitabine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137015719A
Other languages
English (en)
Korean (ko)
Other versions
KR20140037799A (ko
Inventor
레자 올리야이
로렌 와이저
마크 메닝
Original Assignee
길리애드 사이언시즈, 인코포레이티드
얀센 사이언시즈 아일랜드 유씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45094284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101923103(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 길리애드 사이언시즈, 인코포레이티드, 얀센 사이언시즈 아일랜드 유씨 filed Critical 길리애드 사이언시즈, 인코포레이티드
Publication of KR20140037799A publication Critical patent/KR20140037799A/ko
Application granted granted Critical
Publication of KR101923103B1 publication Critical patent/KR101923103B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020137015719A 2010-11-19 2011-11-18 릴피비린 hcl 및 테노포비어 디소프록실 푸마레이트를 포함하는 치료 조성물 Active KR101923103B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41560010P 2010-11-19 2010-11-19
US61/415,600 2010-11-19
PCT/US2011/061515 WO2012068535A1 (en) 2010-11-19 2011-11-18 Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate

Publications (2)

Publication Number Publication Date
KR20140037799A KR20140037799A (ko) 2014-03-27
KR101923103B1 true KR101923103B1 (ko) 2018-11-28

Family

ID=45094284

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137015719A Active KR101923103B1 (ko) 2010-11-19 2011-11-18 릴피비린 hcl 및 테노포비어 디소프록실 푸마레이트를 포함하는 치료 조성물

Country Status (36)

Country Link
US (1) US10857102B2 (https=)
EP (2) EP2826466A1 (https=)
JP (2) JP2014500261A (https=)
KR (1) KR101923103B1 (https=)
CN (2) CN103491948B (https=)
AP (1) AP3816A (https=)
AR (2) AR084500A1 (https=)
AU (3) AU2011329642B2 (https=)
BR (1) BR112013012245B1 (https=)
CA (1) CA2818097C (https=)
CL (1) CL2013001402A1 (https=)
CO (1) CO6761300A2 (https=)
CR (1) CR20130293A (https=)
DK (1) DK2640362T4 (https=)
EA (2) EA201691695A1 (https=)
EC (2) ECSP13012700A (https=)
ES (1) ES2524408T5 (https=)
HK (1) HK1206592A1 (https=)
HR (1) HRP20140946T1 (https=)
IL (1) IL226300B (https=)
MA (1) MA34735B1 (https=)
ME (1) ME01980B (https=)
MX (1) MX347512B (https=)
MY (1) MY185604A (https=)
NZ (1) NZ610729A (https=)
PE (3) PE20211657A1 (https=)
PH (1) PH12013501002A1 (https=)
PL (1) PL2640362T5 (https=)
PT (1) PT2640362E (https=)
RS (1) RS53691B1 (https=)
SG (3) SG190333A1 (https=)
SM (1) SMT201400150B (https=)
TW (1) TWI556840B (https=)
UA (1) UA114075C2 (https=)
WO (1) WO2012068535A1 (https=)
ZA (1) ZA201304481B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1583542T3 (da) 2003-01-14 2008-09-22 Gilead Sciences Inc Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
JP2014500261A (ja) 2010-11-19 2014-01-09 ギリアード サイエンシーズ， インコーポレイテッド リルピビリンＨＣｌおよびフマル酸テノホビルジソプロキシルを含有する治療用組成物
ES2608871T5 (es) 2011-08-16 2024-04-04 Gilead Sciences Inc Alafenamide hemifumarate de tenofovir
CA2779052A1 (en) * 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
WO2015014737A1 (en) * 2013-07-29 2015-02-05 Sanovel Ilac Sanayi Ve Ticaret A.S. Multilayer tablet formulations comprising tenofovir and entecavir
CZ2013985A3 (cs) * 2013-12-09 2015-06-17 Zentiva, K.S. Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
WO2015152433A1 (en) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
US9839212B2 (en) 2015-04-16 2017-12-12 Bio-Lab, Inc. Multicomponent and multilayer compacted tablets
CA2921336A1 (en) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
KR20170003063A (ko) * 2015-06-30 2017-01-09 한미약품 주식회사 테노포비어 디소프록실 함유 경구용 고형제제 및 그 제조방법
WO2017083304A1 (en) 2015-11-09 2017-05-18 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
EP3439639A1 (en) * 2016-04-08 2019-02-13 Shionogi & Co., Ltd. Stabilized solid dosage form
TR201617448A2 (tr) * 2016-11-29 2018-06-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Tenofovi̇r ve emtri̇si̇tabi̇n i̇çeren kati oral farmasöti̇k bi̇leşi̇mler
US10561614B2 (en) * 2017-01-27 2020-02-18 Steerlife India Private Limited Tenofovir granules
CN110958883A (zh) * 2017-06-30 2020-04-03 Viiv保健公司 组合及其用途和疗法
PT3706762T (pt) 2017-12-07 2024-12-05 Univ Emory N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos
JP2022538338A (ja) * 2019-07-03 2022-09-01 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー リルピビリンを用いて小児患者におけるｈｉｖを治療する方法
CN112137981A (zh) * 2020-11-02 2020-12-29 成都晶富医药科技有限公司 富马酸丙酚替诺福韦片及其制备工艺
WO2024211882A1 (en) * 2023-04-07 2024-10-10 Navinta, Llc Stable compositions of rilpivirine hcl in combination with other anti-retroviral agents
CN119174735A (zh) * 2024-09-03 2024-12-24 安徽贝克生物制药有限公司 一种含利匹韦林的复方片及制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021001A1 (en) * 2003-09-03 2005-03-10 Tibotec Pharmaceuticals Ltd. Combinations of a pyrimidine containing nnrti with rt inhibitors
WO2006135933A2 (en) * 2005-06-13 2006-12-21 Bristol-Myers Squibb & Gilead Sciences, Llc Stable fixed-dose unitary formulations containing tenofovir, a surfactant, efavirenz and emtricitabine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL100965A (en) 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AU2002359518A1 (en) 2001-11-27 2003-06-10 Bristol-Myers Squibb Company Efavirenz tablet formulation having unique biopharmaceutical characteristics
DK1583542T3 (da) 2003-01-14 2008-09-22 Gilead Sciences Inc Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
AU2005279158C1 (en) 2004-09-02 2010-12-16 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
BRPI0514871A (pt) 2004-09-02 2008-06-24 Janssen Pharmaceutica Nv cloridrato de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidi nil]amino] benzonitrila
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
AU2006304180A1 (en) 2005-10-14 2007-04-26 Microdose Therapeutx, Inc. Pharmaceutical packaging of an oral dosage combination
RU2008128424A (ru) 2005-12-14 2010-01-20 Сипла Лимитед (In) Фармацевтическая комбинация, включающая нуклеотидный и нуклеозидный ингибиторы обратной транскриптазы (такие как тенофовир и ламивудин) в различных частях дозы
MX2009008935A (es) * 2007-02-23 2009-11-02 Gilead Sciences Inc Moduladores de las propiedades farmacocineticas de productos terapeuticos.
US20080286344A1 (en) 2007-05-16 2008-11-20 Olivia Darmuzey Solid form
WO2008140461A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
AU2008253803A1 (en) * 2007-05-22 2008-11-27 Ultimorphix Technolgies B.V. Tenofovir disoproxil hemi-fumaric acid Co-crystal
WO2009037449A1 (en) 2007-09-18 2009-03-26 Cipla Limited Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors
WO2009106960A2 (en) 2008-02-27 2009-09-03 Aurobindo Pharma Limited Stable compositions of lamivudine, tenofovir and efavirenz
MX2010011963A (es) 2008-05-02 2010-12-06 Gilead Sciences Inc Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
EP2393485B1 (en) 2009-02-06 2015-07-29 Gilead Sciences, Inc. Bilayer tablets comprising elvitegravir, cobicistat, emtricitabine and tenofovir
CN102596958A (zh) 2009-09-21 2012-07-18 吉里德科学公司 用于抗病毒治疗的2’-氟代carba-核苷类似物
WO2011077100A1 (en) 2009-12-24 2011-06-30 Cipla Limited Antiretroviral composition
JP2014500261A (ja) 2010-11-19 2014-01-09 ギリアード サイエンシーズ， インコーポレイテッド リルピビリンＨＣｌおよびフマル酸テノホビルジソプロキシルを含有する治療用組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021001A1 (en) * 2003-09-03 2005-03-10 Tibotec Pharmaceuticals Ltd. Combinations of a pyrimidine containing nnrti with rt inhibitors
WO2006135933A2 (en) * 2005-06-13 2006-12-21 Bristol-Myers Squibb & Gilead Sciences, Llc Stable fixed-dose unitary formulations containing tenofovir, a surfactant, efavirenz and emtricitabine

Also Published As

Publication number Publication date
SMT201400150B (it) 2015-01-15
MA34735B1 (fr) 2013-12-03
AU2016208417A1 (en) 2016-08-18
JP2015131853A (ja) 2015-07-23
PT2640362E (pt) 2014-11-28
AU2016208417B2 (en) 2018-04-05
DK2640362T3 (en) 2014-12-01
PE20211657A1 (es) 2021-08-24
SG10201912527XA (en) 2020-02-27
ME01980B (me) 2015-05-20
ZA201304481B (en) 2022-03-30
PE20170521A1 (es) 2017-05-27
CN103491948B (zh) 2016-11-02
EA201691695A1 (ru) 2017-11-30
CL2013001402A1 (es) 2013-12-27
KR20140037799A (ko) 2014-03-27
PE20140163A1 (es) 2014-02-08
EP2640362B1 (en) 2014-09-10
IL226300B (en) 2019-05-30
NZ610729A (en) 2015-10-30
DK2640362T4 (da) 2022-03-07
ECSP19078196A (es) 2019-11-30
EA025852B1 (ru) 2017-02-28
MX347512B (es) 2017-04-28
UA114075C2 (xx) 2017-04-25
SG190333A1 (en) 2013-06-28
AU2011329642A1 (en) 2013-05-02
CA2818097C (en) 2019-07-30
CA2818097A1 (en) 2012-05-24
AU2018202635A1 (en) 2018-05-10
SG10201509521WA (en) 2015-12-30
CR20130293A (es) 2013-10-03
US20130243857A1 (en) 2013-09-19
CN103491948A (zh) 2014-01-01
HRP20140946T1 (hr) 2015-02-13
ES2524408T3 (es) 2014-12-09
TW201238612A (en) 2012-10-01
EA201390651A1 (ru) 2013-11-29
JP6138851B2 (ja) 2017-05-31
BR112013012245A2 (pt) 2016-08-09
EP2640362B2 (en) 2021-12-01
EP2826466A1 (en) 2015-01-21
MY185604A (en) 2021-05-25
US10857102B2 (en) 2020-12-08
CO6761300A2 (es) 2013-09-30
EP2640362A1 (en) 2013-09-25
MX2013005669A (es) 2013-11-04
PL2640362T5 (pl) 2022-05-02
HK1206592A1 (en) 2016-01-15
AP2013006931A0 (en) 2013-06-30
AU2011329642B2 (en) 2016-08-11
CN106511357A (zh) 2017-03-22
BR112013012245B1 (pt) 2022-09-27
RS53691B1 (sr) 2015-04-30
AR123409A2 (es) 2022-11-30
PH12013501002A1 (en) 2013-09-09
AP3816A (en) 2016-09-30
HK1190064A1 (en) 2014-06-27
PL2640362T3 (pl) 2015-03-31
TWI556840B (zh) 2016-11-11
ECSP13012700A (es) 2013-08-30
WO2012068535A1 (en) 2012-05-24
JP2014500261A (ja) 2014-01-09
AR084500A1 (es) 2013-05-22
ES2524408T5 (es) 2022-04-25

Similar Documents

Publication Publication Date Title
KR101923103B1 (ko) 릴피비린 hcl 및 테노포비어 디소프록실 푸마레이트를 포함하는 치료 조성물
AU2014265327B2 (en) Cenicriviroc compositions and methods of making and using the same
EP3054926B1 (en) Hiv treatment formulation of atazanavir and cobicistat
HK1235695A1 (en) Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
HK1190064B (en) Therapeutic compositions comprising rilpivirin hcl and tenovofir disoproxil fumarate
OA17316A (en) Therapeutic compositions comprising Rilpivirine HCL and Tenofovir Disoproxil Fumarate.
HK40002830A (en) Hiv treatment formulation of atazanavir and cobicistat
HK40002830B (en) Hiv treatment formulation of atazanavir and cobicistat

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 8